^
Association details:
| Biomarker: | PD-1 underexpression + PD-L1 overexpression |
|---|---|
| Cancer: | Solid Tumor |
| Drug Class: | PD1 inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study
Published date:
12/11/2023
Excerpt:
Comparison of treatment outcomes according to combinations of high or low sPD-1 and sPD-L1 levels, however, revealed that patients with low sPD-1 and high sPD-L1 concentrations had a significantly poorer PFS (HR of 1.79 [95% CI, 1.13–2.83], p = 0.01) and a tendency toward poorer OS (HR of 1.70 [95% CI, 0.99–2.91], p = 0.05) compared with all other patients.
DOI:
https://doi.org/10.3389/fimmu.2023.1325462
